To validate whether aspirin-induced FGL1 degradation benefits HCC immunotherapy in vivo, we selected PD-L1 blockade with aspirin for the combination therapy in Hepa 1-6 and H22 tumor models. The gene discussed is FGL1; the disease is hepatocellular carcinoma.